Evidence map›Paper›PMID 32447242›Full record

ArticleCancer epidemiology2020

Contrasting serum biomarker profiles in two Colombian populations with different risks for progression of premalignant gastric lesions during chronic Helicobacter pylori infection.

Mark T Whary, Jose M Restrepo Avenia, Luis E Bravo, Jennifer L Lofgren, Kvin Lertpiriyapong, Robertino Mera-Giler, M Blanca Piazuelo, Pelayo Correa, Richard M Peek, Keith T Wilson and 1 more

Open access · greenAbstract read
In one paragraph

Article in Cancer epidemiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Mark T WharyDivision of Comparative Medicine, Massachusetts Institute of Technology, Cambridge, MA, USA.
Jose M Restrepo AveniaDepartment of Pathology, Universidad Del Valle, Cali, Colombia.
Luis E BravoDepartment of Pathology, Universidad Del Valle, Cali, Colombia.
Jennifer L LofgrenDivision of Comparative Medicine, Massachusetts Institute of Technology, Cambridge, MA, USA.
Kvin LertpiriyapongDivision of Comparative Medicine, Massachusetts Institute of Technology, Cambridge, MA, USA.
Robertino Mera-GilerDivision of Gastroenterology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
M Blanca PiazueloDivision of Gastroenterology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Pelayo CorreaDivision of Gastroenterology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Richard M PeekDivision of Gastroenterology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA; Veterans Affairs Tennessee Valley Healthcare System, Nashville, TN, USA; Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA.
Keith T WilsonDivision of Gastroenterology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA; Veterans Affairs Tennessee Valley Healthcare System, Nashville, TN, USA; Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA.
James G FoxDivision of Comparative Medicine, Massachusetts Institute of Technology, Cambridge, MA, USA; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA. Electronic address: jgfox@mit.edu.
Massachusetts Institute of Technology · USVanderbilt University Medical Center · USUniversidad del Valle · COVA Tennessee Valley Healthcare System · US

Funding

Translational Analysis CoreP30DK058404 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RICHARD M. PEEK · 2002 to 2026
$29.9M
Role of Iron and B-Catenin Activation in Gastric CarcinogenesisP01CA116087 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Kevin L Schey · 2009 to 2026
$27.5M
Reaction and Diffusion of NO in Biological SystemsP01CA026731 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI TANNENBAUM, STEVEN R · 1985 to 2018
$25.4M
Project 3 - Molecular Signatures of Gastric Carcinogenesis in the Host Response to H. pyloriP01CA028842 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI WILSON, KEITH T. · 1985 to 2019
$15.8M
H.Pylori Relationship to Digestive Diseases and CancerR01CA077955 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RICHARD M. PEEK · 2003 to 2026
$9.7M
Helicobacter Pylori and Gastrointestinal BiologyR01DK058587 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PEEK, RICHARD M. · 2001 to 2024
$7.8M
IN VIVO PATHOGENESIS OF HELICOBACTER PYLORIR01AI037750 · NIAID · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI FOX, JAMES G · 1996 to 2009
$3.5M
Targeted chemoprevention of gastric carcinogenesis in high risk populationsR01CA190612 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MORGAN, DOUGLAS, WILSON, KEITH T. · 2014 to 2018
$3.0M
Biomedical Research Training for Veterinary ScientistsT32OD010978 · OD · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI FOX, JAMES G · 2012 to 2017
$2.2M
The Macrophage Reverse Transsulfuration Pathway: A Novel Mediator of Helicobacter pylori ImmunopathogenesisR21AI142042 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI WILSON, KEITH T. · 2019 to 2020
$468k
Dysregulated Polyamine Metabolism in H. pylori-associated Gastric Inflammation and Disease ProgressionI01CX002171 · VA · VETERANS HEALTH ADMINISTRATION · PI Keith T. Wilson · 2020 to 2026
–
Arginine Availability and Metabolism in the Immune Evasion of H. pyloriI01BX001453 · VA · VETERANS HEALTH ADMINISTRATION · PI WILSON, KEITH T. · 2012 to 2019
–
BLRD VA I01 BX001453CSRD VA I01 CX002171NCI NIH HHS P01 CA026731NCI NIH HHS P01 CA028842NCI NIH HHS P01 CA116087NCI NIH HHS R01 CA077955NCI NIH HHS R01 CA190612NIAID NIH HHS R01 AI037750NIAID NIH HHS R21 AI142042NIDDK NIH HHS P30 DK058404NIDDK NIH HHS R01 DK058587NIH HHS T32 OD010978
6 · The paper itself

Abstract

backgroundColombians in coastal Tumaco have a lower incidence of Helicobacter pylori-associated gastric cancer compared to individuals from Tuquerres in the high Andes. This is despite nearly universal prevalence of H. pylori infection and chronic gastritis.

methodsH. pylori infection was confirmed by Steiner stain and serology using African and European-origin strains. Gastric histology and serum inflammatory biomarkers in dyspeptic Tumaco or Tuquerres patients were evaluated to predict progression of gastric lesions.

resultsH. pylori infection was nearly universal by Steiner stain and serology. IgG response to European-origin H. pylori strains were greater than African-origin. High gastric cancer-risk Tuquerres patients, compared to low-risk Tumaco, had significant odds ratios for lesion progression associated with serum IL-5, trefoil factor 3 (TFF3), and low pepsinogen I/II ratio. Sensitivity and specificity for these parameters was 63.8% and 67.9%, respectively, with correctly classifying patients at 66.7%. Most odds ratios for 26 other biomarkers were significant for the town of residency, indicating an environmental impact on Tumaco patients associated with decreased lesion progression.

conclusionAn IL-5 association with progression of gastric lesions is novel and could be evaluated in addition to TFF3 and pepsinogen I/II ratio as a non-invasive prognostic screen. Results suggest Tumaco patients were exposed to infectious diseases beyond H. pylori such as the documented high incidence of helminthiasis and toxoplasmosis. IMPACT: Results support a prior recommendation to evaluate TFF3 and pepsinogen I/II together to predict aggressive gastric histology. Our data indicate IL-5 should be further evaluated as prognostic parameter.

Indexed as

AdultBiomarkersCase-Control StudiesColombiaFemaleHelicobacter InfectionsHelicobacter pyloriHumansIncidenceInterleukin-5MaleMiddle AgedPrecancerous ConditionsStomach NeoplasmsTrefoil Factor-3BiomarkersIL5 protein, humanInterleukin-5TFF3 protein, humanTrefoil Factor-3ColombiaGastric cancerHelicobacter pyloriSerum biomarkers

Identifiers

PMID32447242
PMCPMC7755565
OpenAlexW3026426883

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.